S'abonner

Shouhui Tongbian Capsules induce regression of inflammation to improve intestinal barrier in mice with constipation by targeted binding to Prkaa1: With no obvious toxicity - 28/03/23

Doi : 10.1016/j.biopha.2023.114495 
Chenghong Sun a, b, 1, Yongkang Zhang c, 1, Mingfei Liu d, 1, Zhong Liu b, e, Lihong Pan b, e, Hongbao Liang b, e, Ning Liu b, Shirong Li a, b, Dejun Niu b, e, Xiangzi Li b, e, Bin Li b, e, Lijuan Cui b, e, Jingchun Yao b, e, , Xuefeng Xiao a, , Guimin Zhang b, e,
a School of Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China 
b State Key Laboratory of Generic Manufacture Technology of Chinese Traditional Medicine, Lunan Pharmaceutical Group Co. Ltd., Linyi 276005, China 
c College of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan 250300, China 
d Key Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, China 
e Linyi Key Laboratory for Immunopharmacology and Immunotoxicology of Natural Medicine, Lunan Pharmaceutical Group Co. Ltd., Linyi 273400, China 

Corresponding authors at: State Key Laboratory of Generic Manufacture Technology of Chinese Traditional Medicine, Lunan Pharmaceutical Group Co. Ltd., Linyi 276005, ChinaState Key Laboratory of Generic Manufacture Technology of Chinese Traditional Medicine, Lunan Pharmaceutical Group Co. LtdLinyi276005China⁎⁎Corresponding author.

Abstract

Constipation arising from the poor bowel movement is a rife enteric health problem. Shouhui Tongbian Capsule (SHTB) is a traditional Chinese medicine (TCM) which effectively improve the symptoms of constipation. However, the mechanism has not been fully evaluated. The purpose of this study was to evaluate the effect of SHTB on the symptoms and intestinal barrier of mice with constipation. Our data showed that SHTB effectively improved the constipation induced by diphenoxylate, which was confirmed by shorter first defecation time, higher internal propulsion rate and fecal water content. Additionally, SHTB improved the intestinal barrier function, which was manifested by inhibiting the leakage of Evans blue in intestinal tissues and increasing the expression of occludin and ZO-1. SHTB inhibited NLRP3 inflammasome signaling pathway and TLR4/NF-κB signaling pathway, reduced the number of proinflammatory cell subsets and increased the number of immunosuppressive cell subsets to relieve inflammation. The photochemically induced reaction coupling system combined with cellular thermal shift assay and central carbon metabolomics technology confirmed that SHTB activated AMPKα through targeted binding to Prkaa1 to regulate Glycolysis/Gluconeogenesis and Pentose Phosphate Pathway, and finally inhibited intestinal inflammation. Finally, no obvious toxicity related to SHTB was found in a repeated drug administration toxicity test for consecutive 13 weeks. Collectively, we reported SHTB as a TCM targeting Prkaa1 for anti-inflammation to improve intestinal barrier in mice with constipation. These findings broaden our knowledge of Prkaa1 as a druggable target protein for inflammation inhibition, and open a new avenue to novel therapy strategy for constipation injury.

Le texte complet de cet article est disponible en PDF.

Graphical Abstract




ga1

Le texte complet de cet article est disponible en PDF.

Highlights

Shouhui Tongbian Capsules (SHTB) improves intestinal barrier in constipated mice.
SHTB induce regression of intestinal inflammation by targeted binding to Prkaa1.
Repeated drug administration toxicity test demonstrates the security of SHTB.

Le texte complet de cet article est disponible en PDF.

Abbreviations : 5-HT, AMPK, ANOVA, CETSA, CTL, DNT, ECL, F/B, H&E, HPIC-MS/MS, HPLC-LTQ-Orbitrap/MS, HRMS, ICOS, IL-1β, IL-6, KEGG, LTI, MC, NF-κB, NLRP3, NOAEL, SD, SDS-PAGE, SHTB, SHTBH, SHTBL, SHTBM, SPF, TCA cycle, TCM, Th, TLR4, TNF-α, ZO-1

Chemical compounds studied in this article : Isosakuranin (PubChem CID: 102004611), Emodin-8-glucoside (PubChem CID: 99649), Emodin (PubChem CID: 3220), Hesperetin (PubChem CID: 72281), Luteolin (PubChem CID: 5280445), Diosmetin (PubChem CID: 5281612), Feralolide (PubChem CID: 5317333), Staurosporine (PubChem CID: 44259)

Keywords : Shouhui Tongbian Capsules, Intestinal barrier, Intestinal inflammation, Prkaa1, Repeated drug administration toxicity test


Plan


© 2023  The Authors. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 161

Article 114495- mai 2023 Retour au numéro
Article précédent Article précédent
  • Machine learning for genetic prediction of chemotherapy toxicity in cervical cancer
  • Lu Guo, Wei Wang, Xiaodong Xie, Shuihua Wang, Yudong Zhang
| Article suivant Article suivant
  • Effects of platelet-rich plasma glue placement at the prostatectomy site on erectile function restoration and cavernous nerve preservation in a nerve-sparing prostatectomy rat model
  • Chun-Hou Liao, Chi-Jen Chang, Kuo-Chiang Chen, Chellappan Praveen Rajneesh, Xiao-Wen Tseng, Jai-Hong Cheng, Han-Sun Chiang, Yi-No Wu

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.